Patents by Inventor Robert A. Kramer
Robert A. Kramer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11925991Abstract: A milling device for machining a slot into an inner surface of a casing for a gas turbine engine. The milling device includes a frame assembly including multiple structural guides configured to engage structural features on the inner surface of the casing to maintain an axial position of the milling device relative to a longitudinal axis of the casing. The milling device also includes a milling cutter coupled to the frame assembly. The milling device is configured to be displaced in a circumferential direction relative to the longitudinal axis to machine the slot, via the milling cutter, along the inner surface of the casing in the circumferential direction.Type: GrantFiled: July 14, 2022Date of Patent: March 12, 2024Assignee: GENERAL ELECTRIC COMPANYInventors: Kurt Kramer Schleif, Fabian Gubelmann, Andrew David Ellis, Robert David Jones, Thomas Gloor, Roman Stefan Peter
-
Publication number: 20240023527Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: September 1, 2023Publication date: January 25, 2024Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 11785924Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 5, 2018Date of Patent: October 17, 2023Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 11559049Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 12, 2018Date of Patent: January 24, 2023Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Publication number: 20220340937Abstract: Processes and systems for biologically producing hydrogen gas from organic waste, including food waste. Such a process includes biologically producing hydrogen gas from organic waste by anaerobic fermentation of the organic waste with at least one strain of yeast.Type: ApplicationFiled: September 25, 2020Publication date: October 27, 2022Inventors: Robert A. Kramer, Libbie S.W. Pelter, John A. Patterson
-
Patent number: 11445710Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: January 12, 2018Date of Patent: September 20, 2022Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui D. Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Publication number: 20220075022Abstract: A configurable phased array tile is disclosed including an aperture assembly having a plurality of aperture assembly connectors, a backplane assembly having a plurality of backplane assembly connectors, and a plurality of vertical transmit cards mounted to a corresponding first plurality of aperture assembly connectors and a corresponding first plurality of backplane assembly connectors. The plurality of vertical transmit cards each include a plurality of transmit channels including at least one high power transmit amplifier for powering at least one radiating element mounted to the aperture assembly.Type: ApplicationFiled: February 4, 2021Publication date: March 10, 2022Applicant: MACOM Technology Solutions Holdings, Inc.Inventors: Yasser Al-Rashid, Christopher Dirk Weigand, Daniel Robert Kramer, Nicholas James Ahlquist
-
Patent number: 11237165Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: July 18, 2017Date of Patent: February 1, 2022Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20210347995Abstract: A product for incorporating ultraviolet radiation protection and antimicrobial protection into a synthetic polymer is disclosed which has a quantity of zinc oxide particles with each particle having a surface, a paste, a quantity of synthetic polymer chips, and a quantity of a reactive group for modifying each surface of each zinc oxide particle, the quantity of the reactive group sufficient for forming a bond with the quantity of synthetic polymer chips prior to the quantity of synthetic polymer chips being formed into a fiber.Type: ApplicationFiled: May 24, 2021Publication date: November 11, 2021Inventors: Robert Kramer, Ronald Kramer, Nicholas Marshall, Peter Hauser, Jason Rosenberg
-
Patent number: 10966411Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: October 19, 2009Date of Patent: April 6, 2021Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. de Kruif, Erwin Houtzager
-
Publication number: 20200319181Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: June 19, 2020Publication date: October 8, 2020Applicant: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager
-
Patent number: 10605808Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is a common human, human-like, or humanized light chain. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 27, 2016Date of Patent: March 31, 2020Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. Dekruif, Erwin Houtzager
-
Patent number: 10284626Abstract: The embodiments described herein generally relate to a protocol for implementing data operations, e.g., a version of SMB, atop RDMA transports. In embodiments, systems and methods use the protocol definition, which specifies new messages for negotiating an RDMA connection and for transferring SMB2 data using the negotiated communication. A new protocol message may include new header information to determine message size, number of messages, and other information for sending the SMB2 data over RDMA. The header information is used to accommodate differences in message size requirements between RDMA and SMB2. The SMB Direct protocol allows SMB2 data to be fragmented into multiple individual RDMA messages that a receiver may then logically concatenate into a single SMB2 request or SMB2 response. The SMB Direct protocol also may allow SMB2 to transfer application data via efficient RDMA direct placement and to signal the application data's availability when the transfer is complete.Type: GrantFiled: April 8, 2016Date of Patent: May 7, 2019Assignee: Microsoft Technology Licensing, LLCInventors: Thomas M. Talpey, Gregory Robert Kramer, David Matthew Kruse
-
Patent number: 10246724Abstract: Various embodiments of the present invention pertain to methods for biological production of hydrogen. More specifically, embodiments of the present invention pertain to a modular energy system and related methods for producing hydrogen using organic waste as a feed stock.Type: GrantFiled: November 21, 2016Date of Patent: April 2, 2019Assignee: Purdue Research FoundationInventors: Robert Kramer, Libbie S. Pelter, John A. Patterson
-
Publication number: 20180142006Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142005Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 12, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142003Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 9, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180142002Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 5, 2018Publication date: May 24, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui Daniel PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Publication number: 20180134770Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: ApplicationFiled: January 12, 2018Publication date: May 17, 2018Applicant: Merus N.V.Inventors: Ton LOGTENBERG, Mark THROSBY, Robert A. KRAMER, Rui D. PINTO, Cornelis A. DE KRUIF, Erwin HOUTZAGER
-
Patent number: 9944695Abstract: Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression cassette for the expression of a desired molecule in cells during a certain stage of development in cells developing into mature B cells. Further provided is methods for producing an immunoglobulin from the transgenic, non-human animal.Type: GrantFiled: April 30, 2014Date of Patent: April 17, 2018Assignee: Merus N.V.Inventors: Ton Logtenberg, Mark Throsby, Robert A. Kramer, Rui Daniel Pinto, Cornelis A. De Kruif, Erwin Houtzager